Topics Covered: Science and Technology- developments and their applications and effects in everyday life Achievements of Indians in science & technology; indigenization of technology and developing new technology.
National Biopharma Mission (NBM)
BIRAC has announced that ZyCoV-D, the plasmid DNA vaccine designed and developed by Zydus and partially funded by the Department of Biotechnology (DBT) has initiated Phase I/Phase II clinical trials in healthy subjects, making it the first indigenously developed vaccine for COVID-19 to be administered in humans in India.
- DBT has partnered with Zydus to address rapid development of an indigenous vaccine for COVID-19 under the National Biopharma Mission.
About National Biopharma Mission (NBM):
It is an industry-academia collaborative mission for accelerating biopharmaceutical development in the country.
It was launched in 2017 at a total cost of Rs 1500 crore and is 50% co-funded by World Bank loan.
It is being implemented by the Biotechnology Industry Research Assistance Council (BIRAC).
- Under this Mission, the Government has launched Innovate in India (i3) programme to create an enabling ecosystem to promote entrepreneurship and indigenous manufacturing in the biopharma sector.
It has a focus on following four verticals:
- Development of product leads for Vaccines , Biosimilars and Medical Devices that are relevant to the public health need by focussing on managed partnerships.
- Upgradation of shared infrastructure facilities and establishing them as centres of product discovery/discovery validations and manufacturing.
- Developing human capital by providing specific training.
- Developing technology transfer offices to help enhance industry academia inter-linkages.
- National Biopharma Mission- objectives and components.
- What is Innovate in India (i3) programme?
- About BIRAC.
- Difference between DNA and RNA vaccines.
Discuss the features and significance of NBM.